MP09-20 PROSTATE BIOPSY TARGETED TO PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) FOCI

Abstract

You have accessJournal of UrologyCME1 May 2022MP09-20 PROSTATE BIOPSY TARGETED TO PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) FOCI David Kuppermann, Jeremie Calais, Wayne Brisbane, Elizabeth Tran, Lorna Herbert, Matthias Benz, Johannes Czernin, and Leonard Marks David KuppermannDavid Kuppermann More articles by this author , Jeremie CalaisJeremie Calais More articles by this author , Wayne BrisbaneWayne Brisbane More articles by this author , Elizabeth TranElizabeth Tran More articles by this author , Lorna HerbertLorna Herbert More articles by this author , Matthias BenzMatthias Benz More articles by this author , Johannes CzerninJohannes Czernin More articles by this author , and Leonard MarksLeonard Marks More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002531.20AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: PSMA PET imaging is the most accurate imaging method known for detection of metastatic PCa. PSMA PET may also reveal intra-prostatic cancer. 68Ga-PSMA scanning was approved by FDA in December 2020 for pre-op staging of PCa and to detect possible recurrence. MRI-guided biopsy (MRGB) is the preferred method for diagnosis of prostate cancer (PCa), but PCa may be MRI-invisible (≈15-20%). Herein we study intra-prostatic PSMA focal uptake as a target for biopsy detection of PCa using PET/CT-US fusion (PSMA-guided biopsy, PSMA-GB). METHODS: In a prospective trial, 13 men underwent PSMA PET/CT imaging prior to fusion biopsy at UCLA. Subjects are men with negative prior biopsy (10 MRGB), but continued clinical suspicion of PCa and focal uptake of PSMA in the prostate. Method of PSMA-GB is identical to MRGB (PMID 26749141) but employs US fusion with PET/CT instead of MRI, as detailed previously (PMID: 28607878). Method of Ga-PSMA image acquisition via PET/CT scanning has been reported (PMID: 30920593). Contouring of intra-prostatic foci of PSMA positivity was via Profuse software by co-author J.C. Image fusion & trans-rectal targeted biopsy was via Artemis device (LSM). Detection rate of csPCa ( >GG2) by PSMA-GB was primary endpoint. RESULTS: To date, 13 men have completed study. Median age=71 yrs.; prostate volume=27.7 cc (IQR 22.1, 38.3); PSA density=0.25 ng/ml/cc (IQR 0.10, 0.45 PSMA-GB was successfully completed in all 13 with no more difficulty than usual MRI-GB. Overall detection rate was 9/13 (70%): GG2 in 1, GG3 in 6, and GG4 in 2. Max Cancer Core Length was 4 mm median (IQR 3, 9). 4 PSMA foci were anterior; all 4 contained csPCa. Median SUVmax (standardized uptake value) was 6 in PSMA lesions returning <GG1 findings vs 8.2 in men with csPCa. Median PSAD (density) was higher in men with csPCa (0.25) than others (0.20). Of 5 men with prior radiation, 4 had csPCa on PSMA-GB. CONCLUSIONS: Prostate biopsy, which targets PSMA “hot spots” via PET/CT-US fusion, may lead to detection of clinically significant cancers missed by MRI-guided biopsy. Source of Funding: None © 2022 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 207Issue Supplement 5May 2022Page: e144 Advertisement Copyright & Permissions© 2022 by American Urological Association Education and Research, Inc.MetricsAuthor Information David Kuppermann More articles by this author Jeremie Calais More articles by this author Wayne Brisbane More articles by this author Elizabeth Tran More articles by this author Lorna Herbert More articles by this author Matthias Benz More articles by this author Johannes Czernin More articles by this author Leonard Marks More articles by this author Expand All Advertisement PDF DownloadLoading ...